Carmot Therapeutics Inc, based in Berkeley, CA, is a leading drug discovery and development company that focuses on improving clinical outcomes for individuals living with metabolic diseases such as obesity and diabetes. With a mission to make what matters possible, Carmot Therapeutics utilizes their innovative approach of chemotype evolution to expand the universe of therapeutic potential, offering new possibilities for patients. Recently acquired by Roche in early 2024, Carmot Therapeutics is now a member of the esteemed Roche Group, further strengthening their commitment to advancing healthcare.
Driven by a passion for science and a singular focus on improving the lives of people with obesity and diabetes, Carmot Therapeutics is dedicated to making a difference. Their pipeline of innovative solutions, built on the principles of incretin receptor signaling bias and energy homeostasis, showcases their commitment to developing groundbreaking treatments. With a team of experienced leaders, advisors, investors, and partners, Carmot Therapeutics is at the forefront of scientific advancements in the field of metabolic diseases, offering exciting career opportunities for those ready to contribute to their mission.
Generated from the website